Non-interventional, multicenter, multi-cohort study to investigate the outcomes and safety of atezolizumab treatment in real-life conditions of routine clinical practice. ROC-ATE-2018-01
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Execution start: 30/03/2020
- End of execution: 30/05/2025
- IP: